(e,e,e,e)-squalene is a lipid of Fatty Acyls (FA) class. (e,e,e,e)-squalene is associated with abnormalities such as Hypercholesterolemia and Cataract. The involved functions are known as Process, metaplastic cell transformation, Protein Overexpression, Anabolism and Biosynthetic Pathways. (e,e,e,e)-squalene often locates in Membrane, Protoplasm, Plasma membrane, Tissue membrane and Back. The associated genes with (e,e,e,e)-squalene are Genome, IMPACT gene, GAPDH gene, GTF2I gene and Chromatin. The related lipids are Membrane Lipids, cycloartenol, Sterols, Fatty Acids and Nonesterified Fatty Acids.
To understand associated biological information of (e,e,e,e)-squalene, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
(e,e,e,e)-squalene is suspected in Hypercholesterolemia, Cataract and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with (e,e,e,e)-squalene
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Iorio AM et al. | Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy. | 2003 | Vaccine | pmid:12922092 |
Decaro N et al. | Immunogenicity and protective efficacy in dogs of an MF59â„¢-adjuvanted vaccine against recombinant canine/porcine coronavirus. | 2011 | Vaccine | pmid:21272607 |
Calabro S et al. | Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. | 2011 | Vaccine | pmid:21215831 |
Javelle E et al. | Delayed focal lipoatrophy after AS03-adjuvanted influenza A (H1N1) 2009 vaccine. | 2011 | Vaccine | pmid:21172376 |
Puig-Barberà J et al. | Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age. | 2004 | Vaccine | pmid:15530669 |
Pellegrini M et al. | MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. | 2009 | Vaccine | pmid:19751689 |
Barnett SW et al. | Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. | 1997 | Vaccine | pmid:9234536 |
Forrest HL et al. | Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets. | 2009 | Vaccine | pmid:19406182 |
Schultze V et al. | Safety of MF59 adjuvant. | 2008 | Vaccine | pmid:18462843 |
Hilgers LA et al. | A novel non-mineral oil-based adjuvant. I. Efficacy of a synthetic sulfolipopolysaccharide in a squalane-in-water emulsion in laboratory animals. | 1994 | Vaccine | pmid:8085385 |
Hilgers LA et al. | A novel non-mineral oil-based adjuvant. II. Efficacy of a synthetic sulfolipopolysaccharide in a squalane-in-water emulsion in pigs. | 1994 | Vaccine | pmid:8085386 |
Byars NE et al. | Vaccinating guinea pigs with recombinant glycoprotein D of herpes simplex virus in an efficacious adjuvant formulation elicits protection against vaginal infection. | 1994 | Vaccine | pmid:8165851 |
Ansaldi F et al. | Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. | 2010 | Vaccine | pmid:20433807 |
Iorio AM et al. | Influenza viruses and cross-reactivity in healthy adults: humoral and cellular immunity induced by seasonal 2007/2008 influenza vaccination against vaccine antigens and 2009 A(H1N1) pandemic influenza virus. | 2012 | Vaccine | pmid:22245606 |
Ott G et al. | Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. | 1995 | Vaccine | pmid:8578842 |
Heineman TC et al. | A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. | 1999 | Vaccine | pmid:10438046 |
De Donato S et al. | Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. | 1999 | Vaccine | pmid:10462245 |
Tsai T et al. | Exposure to MF59-adjuvanted influenza vaccines during pregnancy--a retrospective analysis. | 2010 | Vaccine | pmid:19969117 |
Pietrella D et al. | A beta-glucan-conjugate vaccine and anti-beta-glucan antibodies are effective against murine vaginal candidiasis as assessed by a novel in vivo imaging technique. | 2010 | Vaccine | pmid:20038431 |
Camilloni B et al. | An influenza B outbreak during the 2007/2008 winter among appropriately immunized elderly people living in a nursing home. | 2010 | Vaccine | pmid:20846530 |
O'Hagan DT et al. | The mechanism of action of MF59 - an innately attractive adjuvant formulation. | 2012 | Vaccine | pmid:22682289 |
Yu S et al. | Novel Th1-biased adjuvant, SPO1, enhances mucosal and systemic immunogenicity of vaccines administered intranasally in mice. | 2012 | Vaccine | pmid:22709954 |
Radosević K et al. | Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants. | 2008 | Vaccine | pmid:18514980 |
Brito LA et al. | An alternative renewable source of squalene for use in emulsion adjuvants. | 2011 | Vaccine | pmid:21723355 |
Black S et al. | Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis. | 2010 | Vaccine | pmid:20813217 |
de Bruijn I et al. | Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. | 2007 | Vaccine | pmid:18063446 |
Wack A et al. | Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. | 2008 | Vaccine | pmid:18162266 |
Tetsutani K and Ishii KJ | Adjuvants in influenza vaccines. | 2012 | Vaccine | pmid:23084848 |
Nielsen AB et al. | Immune response after one or two doses of pandemic influenza A (H1N1) monovalent, AS03-adjuvanted vaccine in HIV infected adults. | 2012 | Vaccine | pmid:23036498 |
Parretta E et al. | Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination. | 2011 | Vaccine | pmid:21406267 |
Poder A et al. | An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age. | 2014 | Vaccine | pmid:24252703 |
Dediukhina EG and Eroshin VK | [Hydrocarbon biosynthesis by microorganisms]. | 1973 Nov-Dec | Usp Sovrem Biol | pmid:4593530 |
PerederiÄ OF and Morozova RP | [Squalene and sterols of rat stomach tissue and the effect of acetylsalicylic acid on their content]. | 1978 Nov-Dec | Ukr. Biokhim. Zh. | pmid:749299 |
Morozova RP et al. | [Separation of lipid extract from animal blood and tissues and isolation of squalene and sterols from it]. | 1982 Jul-Aug | Ukr. Biokhim. Zh. | pmid:7135500 |
Vendt VP | [Studies in the field of chemistry, biochemistry and photobiochemistry of sterols]. | 1975 Sep-Oct | Ukr Biokhim Zh | pmid:1105921 |
Sanina OL and Datsenko ZM | [Sterol composition of sarcolemma in normal rabbits and in experimental muscular dystrophy]. | 1975 Nov-Dec | Ukr Biokhim Zh | pmid:1202710 |
Ihara T | [Evaluation of alum-adjuvanted whole virus influenza vaccine and future aspects of influenza A (H1N1) 2009 vaccine]. | 2010 | Uirusu | pmid:20848866 |
Laursen AB | [Dangerous adjuvant in swine influenza vaccine]. | 2009 | Ugeskr. Laeg. | pmid:19866499 |
Bruun Laursen A | [Catastrophic consequences of Pandemrix swine flu vaccine containing squalene]. | 2013 | Ugeskr. Laeg. | pmid:23833781 |
Mølbak K | [Squalene unlikely sinner]. | 2013 | Ugeskr. Laeg. | pmid:23833782 |
Moebius FF et al. | Genetic defects in postsqualene cholesterol biosynthesis. | 2000 | Trends Endocrinol. Metab. | pmid:10707051 |
Siirtola A et al. | Cholesterol absorption and synthesis in pediatric kidney, liver, and heart transplant recipients. | 2006 | Transplantation | pmid:16477216 |
Gylling H et al. | Cholesterol synthesis prevails over absorption in metabolic syndrome. | 2007 | Transl Res | pmid:17543849 |
Johnson WS | Nonenzymic biogenetic-like olefinic cyclizations. | 1967 | Trans N Y Acad Sci | pmid:5237390 |
Sunthornandh P and Ratanabanangkoon K | A comparative study of three vehicles on antibody responses against elapid snake neurotoxin immunogens. | 1994 | Toxicon | pmid:8079368 |
Kuroda Y et al. | Distinctive patterns of autoimmune response induced by different types of mineral oil. | 2004 | Toxicol. Sci. | pmid:14718649 |
Flint OP et al. | Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. | 1997 | Toxicol. Appl. Pharmacol. | pmid:9221828 |
Uchino T et al. | Potent protecting effects of Catuaba (Anemopaegma mirandum) extracts against hydroperoxide-induced cytotoxicity. | 2004 | Toxicol In Vitro | pmid:15046771 |
Yockel S and Schatz GC | Dynamic QM/MM: a hybrid approach to simulating gas-liquid interactions. | 2012 | Top Curr Chem | pmid:21506003 |
Hayakawa K and Matsuo I | Effects of PUVA therapy on skin surface lipids: skin surface lipid peroxidation in psoriasis vulgaris and its biological significance. | 1986 | Tokai J. Exp. Clin. Med. | pmid:3672560 |